Table 1 Baseline characteristics of the subjects included in 1994, before the start of the clinical trial
All participants | 150 µg/kg annually | 800 µg/kg annually | 150 µg/kg 3-monthly | 800 µg/kg 3-monthly | |
|---|---|---|---|---|---|
No. of subjects | 485 | 126 | 122 | 125 | 112 |
Mean age ± SD | 36.9 ± 12.0 | 36.4 ± 11.4 | 38.1 ± 12.4 | 36.7 ± 11.9 | 36.6 ± 12.3 |
Mean weight ± SD (kg) | 63.0 ± 8.0 | 62.7 ± 8.2 | 64.3 ± 7.1 | 62.4 ± 8.5 | 62.7 ± 8.0 |
Mean no. of nodules in 1994 ± SD | 5.7 ± 2.8 | 5.5 ± 2.5 | 5.8 ± 2.3 | 5.6 ± 3.2 | 5.9 ± 2.9 |
Median no. of nodules in 1994 (IQR) | 5 (4–7) | 5 (4–7) | 6 (4–7) | 5 (3–7) | 6 (4–7) |
CMFL in the village of residence: | |||||
Low (n, %) | 50 (10.3) | 10 (7.9) | 12 (9.8) | 18 (14.4) | 10 (8.9) |
Middle (n, %) | 135 (27.8) | 39 (31.0) | 37 (30.3) | 30 (24.0) | 29 (25.9) |
High (n, %) | 300 (61.9) | 77 (61.1) | 73 (59.8) | 77 (61.6) | 73 (65.2) |
Geometric mean of MFD | 56.0 | 64.7 | 50.8 | 48.7 | 61.8 |
Median of MFD (IQR) | 79 (27–171) | 91 (34–197) | 71 (26–157) | 74 (24–143) | 84 (28–187) |